<div id="readability-page-1"><p>Citi analyst Yigal Nochomovitz maintained a Buy rating on Summit Therapeutics on December 2 and set a price target of $131.90. The company’s shares closed yesterday at $17.25.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Neurocrine, and ACADIA Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of <span>4.7%</span> and a 39.51% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Summit Therapeutics with a $39.09 average price target.</p></div>

SMMT

<p>Citi analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics with a price target of $131.90, while shares closed at $17.25. The analyst has a 4.7% average return and a 39.51% success rate. The consensus rating for Summit Therapeutics is Moderate Buy with a $39.09 average price target.</p>

Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)